Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
APLS | US
-0.97
-3.41%
Healthcare
Biotechnology
30/06/2024
04/10/2024
27.51
28.04
28.37
27.33
Apellis Pharmaceuticals Inc. a commercial-stage biopharmaceutical company focuses on the discovery development and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria cold agglutinin disease C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis amyotrophic lateral sclerosis and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006 a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030 a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham Massachusetts.
View LessStrong Revenue Growth (> 10%)
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
62.0%1 month
57.2%3 months
56.9%6 months
56.3%-
-
13.58
1.80
0.52
-12.12
5.89
-
-311.30M
3.35B
3.35B
-
-14.75
-
110.30
-109.19
13.93
17.33
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
7.91
Range1M
15.25
Range3M
15.78
Rel. volume
0.65
Price X volume
40.83M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Merus N.V | MRUS | Biotechnology | 51.78 | 3.53B | 2.41% | n/a | 1.48% |
MoonLake Immunotherapeutics | MLTX | Biotechnology | 55.28 | 3.48B | 6.68% | n/a | 0.64% |
TG Therapeutics Inc | TGTX | Biotechnology | 22.23 | 3.44B | -0.67% | 35.04 | 63.38% |
Dynegy Inc | DYN | Biotechnology | 32.58 | 3.27B | -8.35% | n/a | 3.32% |
Iovance Biotherapeutics Inc | IOVA | Biotechnology | 10.46 | 3.17B | 7.17% | n/a | 10.63% |
Amicus Therapeutics Inc | FOLD | Biotechnology | 10.6 | 3.14B | 0.09% | n/a | 335.08% |
Xenon Pharmaceuticals Inc | XENE | Biotechnology | 40.73 | 3.09B | -0.27% | n/a | 1.19% |
Rhythm Pharmaceuticals Inc | RYTM | Biotechnology | 49.63 | 3.03B | -2.71% | n/a | 642.15% |
Kymera Therapeutics Inc | KYMR | Biotechnology | 43.06 | 2.83B | -4.31% | n/a | 12.87% |
PTC Therapeutics Inc | PTCT | Biotechnology | 35.1 | 2.70B | -3.65% | n/a | -40.35% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
LCI Industries | LCII | Recreational Vehicles | 118.67 | 3.02B | -1.21% | 25.17 | 77.66% |
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -12.12 | 0.76 | Cheaper |
Ent. to Revenue | 5.89 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 13.58 | 14.10 | Par |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 56.87 | 74.67 | Lower Risk |
Debt to Equity | 1.80 | -1.82 | Expensive |
Debt to Assets | 0.52 | 0.26 | Expensive |
Market Cap | 3.35B | 3.73B | Par |